ChemicalBook > Product Catalog >API >Antineoplastic agents >Other antineoplastic Drugs >Lenalidomide

Lenalidomide

Lenalidomide Suppliers list
Company Name:Taizhou Creating Chemical Co., Ltd  Gold
Tel:86-576 88827176 18906581668
Email:post@creatingchem.com
Company Name:Jinan Kaypharm Chemical Co.,Ltd.  Gold
Tel:0531-86986780,13153183025
Email:sales@kaypharm.cn
Company Name:Shanghai TaoSu Biochemical Technology Co., Ltd.  Gold
Tel:021-33632979
Email:info@tsbiochem.com
Company Name:Jinan Aery Pharmaceutical Co,.Ltd  Gold
Tel:86-0531-81263406
Email:sales@aerpharm.com;andmchem@gmail.com
Company Name:Beijing Hope International Pharmaceutical Technology Development Co., Ltd  Gold
Tel:010-67886402
Email:liping@hopelife.cn
Lenalidomide Basic information
Antitumor Drug
Product Name:Lenalidomide
Synonyms:lenalidomide;3-(7-amino-3-oxo-1h-isoindol-2-yl)piperidine-2,6-dione;LenalidomideLenalidomide; 1-Oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline;3-(4-Amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidinedione;CC-5013;Revlimi;Lenalidomide(other anti-cancers)
CAS:191732-72-6
MF:C13H13N3O3
MW:259.26062
EINECS:
Product Categories:Molecular Targeted Antineoplastic;Intermediates & Fine Chemicals;Pharmaceuticals;Amines;Heterocycles;Inhibitor;CC-5013;Inhibitors
Mol File:191732-72-6.mol
Lenalidomide Structure
Lenalidomide Chemical Properties
mp 269-271°C
storage temp. -20°C Freezer
CAS DataBase Reference191732-72-6(CAS DataBase Reference)
Safety Information
HazardClass IRRITANT
MSDS Information
Lenalidomide Usage And Synthesis
Antitumor DrugLenalidomide is a kind of antitumor drugs that developed by American biological pharmaceutical companies. Its chemical structure is similar with thalidomide. It has many functions such as anti-tumor, immune regulation and anti-angiogenesis. It can inhibit the secretion of inflammatory cytokines, and increase the secretion of peripheral blood mononuclear anti-inflammatory cytokines. Vitro tests show that lenalidomide can inhibit the hyperplasia of some cell lines such as namalwa cell. It can inhibit the growth of patients’ multiple myeloma cells and MM1S cell. In addition, lenalidomide also can inhibit the expression of oxidase-2 (COX-2), but it has no effect on COX-1. Two multicenter randomized double-blind placebo-controlled clinical studies evaluate the safety and curative effect of lenalidomide that is used for multiple myeloma. The primary efficacy end point of the studies is time to progression (TTP). The interim analysis shows that TTP of the combination group is significantly superior to dexamethasone group. Recent clinical research results show that lenalidomide not only has curative effect on treating MDS and MM, but also on treating myeloma, leukemia, metastatic renal cell carcinoma, solid tumor, idiopathic generalized amyloidosis and systemic bone marrow fibrosis disease with marrow unripe.
Lenalidomide is a new derivative of thalidomide. But its teratogenic toxicity has not found. Its effectiveness is 100 times stronger than thalidomide. According to the result of three clinical trials, lenalidomide is the most effective drug in the treatment of multiple myeloma. More than half of patients can prolong survival time to more than 3 years after taking the drug. In addition, it is also the only effective drugs to treat myelodysplastic syndrome (MDS). Clinical results find that 64% of the patients with MDS need not use blood transfusion after treated by lenalidomide.
In December 2005, the US Food and Drug Administration (FDA) approved lenalidomide to be used in the treatment of myelodysplastic syndrome (MDS).
In March 2006, the FDA approved lenalidomide that was produced by American Celgene Biological Pharmaceutical Companies to be used in the treatment of multiple myeloma (MM).
On September 23, 2011, the European Medicines Agency (EMA) released information that they have confirmed that the benefits of lenalidomide(trade name: Revlimid) to be used in the treatment of patients group that was approved outweighed the risks. Meanwhile they warned the doctor the risk of the drug to cause new cancer cases. Lenalidomide has been used with dexamethasone to treat adult patients with multiple myeloma that has received at least one treatment. Three new studies show that the incidence of new cancer will be increased in the patients with newly diagnosed multiple myeloma treated by lenalidomide and other combined treatment increased incidence of cancer.
The above information is edited by the Chemicalbook Geqian.
Chemical PropertiesYellow Solid
UsageImmunomodulatory drug; analog of Thalidomide.
UsageLenalidomide (Revlimid, CC-5013) is a TNF-α secretion inhibitor with IC50 of 13 nM.
UsageLovastatin content <1% 98%
UsageA Thalidomide analog known to have immunomodulatory properties
Lenalidomide Preparation Products And Raw materials
Tag:Lenalidomide(191732-72-6) Related Product Information
Mitindomide Phthalimidine, 2-(2,6-dioxopiperiden-3-yl). 3-(N-ACETYL-N-METHYLAMINO)PIPERIDINE Lenalidomide AMINO ACIDS 4,4-Piperidinediol hydrochloride Tris Base 6-Aminocaproic acid Dutasteride Indometacin Haloperidol Glycine 2-Amino-5-chlorobenzophenone 3-Aminoacetophenone 1-Oxa-4-azacyclohexane Thalidomide ALTRENOGEST 1-(2,6-Dichlorophenyl)indolin-2-one